Clinical trial NCT06078423: A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)
Official title: Randomized, Blind, Phase III Clinical Trial Comparing the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (MRC-5 Cells) With a 5-dose Program and a 4-dose (2-dose First-dose) Program
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rabies Vaccine Adverse Reaction
Keywords: Safety
Efficacy
Lead sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Sponsor GmbH
First posted: 2023-10-11
Enrollment: 1880
Sex: ALL
Minimum age (years): 10
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Similar vaccine control
Primary purpose: PREVENTION

Brief summary: This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.Phase 1 and Phase 2

Detailed description: This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.

Phase 1: 40 adult subjects aged 18-60 were randomly assigned to receive the trial vaccine in a 1:1 ratio according to a 5-dose immunization program (0, 3, 7, 14, 28 days) or a 4-dose immunization program (0, 7, 21 days (2 doses for the first dose). The number of recipients for each immunization program was 20. All subjects in the adult group underwent a preliminary safety assessment 7 days after the first dose of vaccination (before the third dose of vaccine), but did not meet the suspension/termination criteria. A further 40 underage subjects aged 10-17 were enrolled in the same order as the adult group, and all subjects underwent a preliminary safety assessment 7 days after the full dose of vaccination. If they did not meet the suspension/termination criteria, they entered the second phase of the study.

Phase 2: A total of 1800 subjects aged 10 to 60 years old were randomly assigned to three groups in a 1:1:1 ratio, namely the 5-dose experimental group (vaccinated with the 5-dose program), the 5-dose control group (vaccinated with the 5-dose program), and the 4-dose experimental group (vaccinated with the 4-dose program). All subjects collected blood samples before the first dose, 7 days after the first dose, 14 days after the first dose, and 14 days after the entire dose for immunogenicity evaluation; Subjects who meet the requirements for immune persistence observation in the plan shall collect blood samples 3 months after the full vaccination, and the experimental group subjects shall also collect blood samples 12 months after the full vaccination for immune persistence evaluation.

Collect all AEs from participants within 30 minutes after each dose, collected AEs within 0-7 days after each dose (if the interval from the current dose to the next dose is less than 7 days, the collection period shall be based on the actual interval between the two doses), all non collected AEs within 30 days after the first dose to the entire dose, and all serious adverse events (SAE) within 6 months after the first dose to the entire dose.

Eligibility criteria: Inclusion Criteria:

* Age range from 10 to 60 years old;
* Willing to participate in this experiment and sign an informed consent or notification form;
* The subjects themselves or/and their guardians promise to comply with the requirements of the clinical research protocol;
* Under the age of 14 (including 14 years old), the axillary body temperature is less than 37.5 ℃, and above the age of 14, the axillary body temperature is less than 37.3 ℃

Exclusion Criteria:

* Have a history of rabies vaccine immunization or use of rabies virus passive immunity preparations;
* Have a history of injury to dogs or other mammals within 12 months prior to the first vaccination;
* Have used blood products within 4 months before the first vaccination;
* Inoculate any vaccine within 14 days before the first vaccination;
* Have used other research or unregistered products (drugs or vaccines) within one month before the first vaccination, or have planned to participate in other clinical studies after enrollment in this clinical study;
* Suffering from congenital or acquired immune deficiency. Receiving immunosuppressive therapy, such as long-term (oral) systemic glucocorticoid therapy (continuous (oral) systemic glucocorticoid therapy for more than 2 weeks, such as prednisone or similar drugs);
* Have a history of convulsion, epilepsy, encephalopathy, psychosis or family history;
* Allergic to any component in the study vaccine (such as human albumin, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, sucrose, maltose, etc.); Have a history of severe allergies, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, and local allergic necrosis reaction (Arthur reaction);
* Have any previous history of serious side effects from vaccines or drugs, such as urticaria, skin eczema, respiratory difficulties, vascular and neurological edema, etc;
* Individuals with acute febrile diseases (body temperature ≥ 38.5 ℃) and infectious diseases within 3 days before vaccination;
* Having congenital heart disease, developmental disorder or chronic disease, such as asthma, diabetes, thyroid disease;
* Suffering from urticaria within one year before receiving the experimental vaccine;
* Blood pressure: systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 100mmHg (regardless of medication);
* Suffering from thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection);
* Women of childbearing age who have a positive urine pregnancy test, or have a fertility plan during pregnancy, lactation, or within 2 months;
* Any situation that the researcher believes may affect the evaluation of the experiment

Primary outcomes:
measure: Antibody positive conversion rate - Immunogenicity endpoint
timeFrame: up to 14 days after the first/full dose of vaccination
measure: Geometric mean concentration - Immunogenicity endpoint
timeFrame: 14 days after the first/full dose of vaccination
measure: Incidence of Adverse Events [Safety and Tolerability]
timeFrame: within 30 minutes after each dose of vaccination
measure: Incidence of Adverse Events [Safety and Tolerability]
timeFrame: within 0-7 days after each dose of vaccination
measure: Incidence of Adverse Events [Safety and Tolerability]
timeFrame: within 30 days after the first dose of vaccination to the full course of vaccination
measure: Incidence of Adverse Events [Safety and Tolerability]
timeFrame: within 6 months after the first dose administration and the entire vaccination process
Secondary outcomes:
measure: Antibody positive conversion rate - Immunogenicity endpoint
timeFrame: 7 days after the first dose of vaccination；3 month after full dose of vaccination；
measure: Geometric mean concentration - Immunogenicity endpoint
timeFrame: 7 days after the first dose of vaccination;3 month after full dose of vaccination；
measure: Antibody positive conversion rate - Immunogenicity endpoint
timeFrame: 12 month after full dose of vaccination；
measure: Geometric mean concentration - Immunogenicity endpoint
timeFrame: 12 month after full dose of vaccination；
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan Provincial Center for Disease Control and Prevention
state: Hunan
Study officials:
affiliation: Hunan Provincial Center for Disease Control and Prevention
name: Fangjun Li, Bachelor
role: PRINCIPAL_INVESTIGATOR
References: